This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Impax Labs, Tower Holdings settle with FTC over merger

( March 6, 2015, 15:09 GMT | Official Statement) -- MLex Summary: Pharmaceutical companies Impax Laboratories and Tower Holdings have reached a settlement agreement with the US Federal Trade Commission resolving charges that their proposed merger would likely be anticompetitive. Under the settlement, Impax Laboratories and Tower Holdings have agreed to divest all of CorePharma’s rights and assets to generic pilocarpine tablets and generic ursodiol tablets to Perrigo. CorePharma is an operating subsidiary of Tower Holdings.See the document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login